William Garrett Nichols - 29 Nov 2024 Form 4 Insider Report for Candel Therapeutics, Inc. (CADL)

Role: Chief Medical Officer
Signature: /s/ Charles Schoch, as Attorney-in-Fact for William Garrett Nichols
Issuer symbol: CADL
Transactions as of: 29 Nov 2024
Net transactions value: -$63,482
Form type: 4
Filing time: 03 Dec 2024, 17:47:24 UTC
Previous filing: 19 Jul 2024
Next filing: 10 Jan 2025
SEC: View on sec.gov

Quoteable Key Fact

"William Garrett Nichols filed Form 4 for Candel Therapeutics, Inc. (CADL) on 03 Dec 2024."

Quick Takeaways

This page summarizes William Garrett Nichols's Form 4 filing for Candel Therapeutics, Inc. (CADL).
1 reported transaction and 0 derivative rows are listed below.
Filing timestamp: 03 Dec 2024, 17:47.

What Changed

Previous filing in this sequence was filed on 19 Jul 2024.
Current net transaction value: -$63,482.

Why This Matters

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Official SEC Source

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

See Original Filing

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CADL	Common Stock	Sale	$63,482	-13,935	-12%	$4.56	100,547	29 Nov 2024	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units pursuant to the Issuer's mandatory sell to cover policy, which requires sales in an amount sufficient to cover tax withholding obligations associated with the vesting events, and the sales do not represent discretionary sales by the Reporting Person.

Content

The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units pursuant to the Issuer's mandatory sell to cover policy, which requires sales in an amount sufficient to cover tax withholding obligations associated with the vesting events, and the sales do not represent discretionary sales by the Reporting Person.